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Abstract
The utilization of artificial intelligence (AI) in healthcare has been steadily increasing, but the regulation of AI is challenging. Inspired by the recently proposed European AI regulation, we conducted a
case study among Finnish healthcare stakeholders to identify challenges that current regulation of AIbased healthcare technology (AIHT) poses to development of AIHT, and what the potential consequences of the recently proposed European AI regulation would be for AIHT development. One of the
main challenges we identified is the already existing ambiguity arising from several regulations that
AIHT are subject to. More importantly, we found that this ambiguity would even increase through a
European AI regulation. Another important finding is that the European AI Act might hamper innovation
in AIHT and decelerate the development of AIHT. Our main contribution is to the recent information
systems research opening on regulation of technology.
Keywords: Artificial intelligence, AI regulation, Healthcare technology, Ambiguity, AI Act, Digital
transformation
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Introduction

During the past ten years, one of the most disruptive technologies has been artificial intelligence (AI).
The utilization of AI is also increasing in the field of healthcare, and today there are many different
applications and innovations that try to respond and solve emerging problems of our healthcare system
(Kelly et al., 2019). Patient safety, security, privacy, and ethics are fundamentals that guide healthcare
practices (Polit and Beck, 2017), and therefore all technologies that are targeted at healthcare need to be
validated to prove patient safety and efficacy (Bohr and Memardazeh, 2020).
There are few limitations that decelerate the use of AI in healthcare (Reddy et al., 2020), and one significant, fundamental limitation is that the healthcare sector is justifiable highly regulated (May et al.,
2020). Medical devices (MD), including medical software (Hermon et al., 2021), are regulated through
numerous laws and regulations that focus on different aspects such as demonstrating the safety and
medical-technical performance of the MD, software life cycle processes for the MD software, quality
management systems for the MD manufacturers, and application of risk management to the MD
(Karrenbauer et al. 2019). While AI is being increasingly integrated in MDs (Kelly et al., 2019), current
regulations that concern the MD development do not specifically address AI. This absence of “AI” in
regulation has also been observed in the context of explainable AI in auditing (Rebstadt et al., 2022). A
lack of a clear regulation of AI use may slow AI implementation in organizations (Bérubé et al., 2021).
To address this “regulatory vacuum” of AI, the European Commission (2021a) has presented a new
proposal for the first legal European Union-wide framework on AI: the Artificial Intelligence Act (AI
Act). The AI Act classifies AI systems into four risk classes: unacceptable risk, high risk, limited risk,
and minimal risk. The AI Act requires providers and users of high-risk AI systems to comply with rules
on data and data governance, documentation, and record-keeping, transparency, and provision of information to users, human oversight, robustness, accuracy, and security. For the most part, an AI system is
classified as high-risk based on the context in which the system would be used (e.g., access to and
enjoyment of essential public services and benefits). However, while the use of AI in healthcare per-se
is not proposed to be high-risk, all certified MDs that utilize AI would be classified as high-risk AI
systems. While the AI Act is expected to become effective in 2024, the proposal has already caused
public discussion related to the development and use of AI-based healthcare technology (AIHT) in Europe, including in Finland.
Several IS articles identified research opportunities for IS research related to AI in organizations (see
Benbya et al., 2021; Nguyen et al., 2022; Collins et al., 2021 for detailed research agendas and future
research questions). Amongst these, the regulation of AI has been identified only by Collins et al. (2021)
as a potential area for future AI-related IS research. This is somewhat surprising, given that there has
been a recent call for IS research on the regulation of IT (see Gozman et al., 2020), and given that legal
conditions have been identified as an environmental determinant that triggers and shapes the digital
transformation (Hanelt et al., 2021; Vial, 2019), which is one major interest in IS research. Answering
to the call for IS research to get involved into regulation discussions “to inform and advance AI regulation” (Reinecke et al. 2021, p. 1), and against the practical background of the proposed AI Act that
would classify all MDs as high risk, we consider the development of AIHT from the perspective of legal
regulation (Blind et al., 2017; Martin and Matt, 2018) and ask the question:
RQ: What challenges do healthcare stakeholders see in the current regulation of AIHT, and what would
be potential consequences of future AI regulation for the development of AIHT?
We conducted an empirical case study in the Finnish healthcare technology industry and interviewed
different stakeholders to identify the challenges that organizations developing AIHT currently face, and
what challenges they see to arise from the AI Act proposal and its implementation. We contribute with
this research to the recent IS opening on the legal regulation of technology.
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Related research – Challenges of AI regulation in healthcare

The IS community has addressed diverse topics related to AI. However, the regulation of technology,
including that of AI, has received scant attention. With regulation, we here mean “legal” regulation as
“any form of ‘coercive rule setting’ by governments to influence market activity and economic actors’
behavior” (Blind et al., 2017; Martin and Matt, 2018, p. 2). Therefore, we turn to other disciplines –
mostly the medical and legal research fields – to get an understanding of the challenges of AI regulation
in the healthcare.
Healthcare specific regulation of AI is diverse, and different national or regional regulations or laws aim
to indirectly regulate AI in healthcare (Jaremko et al., 2019; Recht et al., 2020). The regulation of AI in
healthcare is necessary to protect patients’ freedom, fundamental rights, as well as their safety and privacy (Mattei, 2020). AI technologies require a lot of data (Forcier et al., 2019), and this increases challenges for healthcare organizations, because they need to solve and manage issues related to data privacy
issues (e.g., anonymization, data access related questions), data sharing, and appropriate use of data
(Ahmad et al., 2020). In Europe, the General Data Protection Regulation (GDPR) regulates the processing of personal data. The interpretation of how to interpret the GDPR and comply with it has been
challenging (Grundstrom et al., 2019). AIHT often utilize sensitive personal data, and certain requirements set in the GDPR, such as the consumer’s right to erase personal details in the name of the privacy
(Shintre et al., 2019) cause challenges for the development and use of AIHT. As personal and nonpersonal data can be scattered and non-reliable (Sunrise Winter and Davidson, 2019), it may cause bias
(Ahmad et al., 2020) and medical errors (Smith and Heath Jeffery, 2020). Further, getting patient consent – which is required in order to be allowed to process the data - may be impossible or impractical in
some cases, e.g., if the patient is unconscious or cognitively impaired (Bester et al., 2016).
One challenge in healthcare is the ‘regulatory vacuum’ (i.e., existing laws or regulations do not cover a
certain aspect) regarding liability in the context of AIHT, because there is a lack of clear standards
addressing legal responsibility if AI technologies cause harm (Carter et al., 2020). Another challenge is
the black box phenomenon (Forcier et al., 2019; Currie and Hawk, 2020), which is related to transparency: because functioning of AI may be not traceable, it is challenging to guarantee the data safety and
to understand how, for example, a specific decision was made (Currie and Hawk, 2020; Grant et al.,
2020; Laï et al., 2020). The black box phenomenon and questions of liability are closely related, because
liability issues are always present when AI makes wrong decision or decision that causes harm (Laï et
al., 2020; Sullivan and Schweikart, 2019). More generally, the lack of legal frameworks that consider
responsibility and medical malpractices by machines (Mattei, 2020; Sullivan and Schweikart, 2019)
causes challenges.
Another challenge in the healthcare that AI faces is the lack of validation of AI technologies (Recht et
al., 2020). Eventually, if AI has got an appropriate regulatory framework and evidence suggests that the
use of AI is safe and recommended, the next challenge is how to integrate AI technology into clinical
workflow (Grant et al., 2020). In addition, healthcare is quite often a sensitive field with many ethical
dilemmas, and the development of AI technologies have created new ethical dilemmas that developers
of AI systems as well as healthcare professionals and patients face (Jaremko et al., 2019). Therefore,
from the regulatory perspective, ethical issues that arise in healthcare as a result of AI technology need
a clear regulatory framework (Allen, 2019). The European Commission has created ethical guidelines
for trustworthy AI (European Commission, 2019) and these guidelines should be considered also with
AI technologies in the field of healthcare.

3

Research methodology

To answer the research question, we conducted a qualitative case study among Finnish healthcare stakeholders to gain an understanding of the current regulation of AIHT and the potential effects of future AI
regulation, specifically the European AI Act.
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Data collection. We conducted purposeful sampling (Higginbottom, 2004) and identified 18 informants
who represented central stakeholder-clusters of healthcare research, development, and innovation (RDI)
in Finland (Ministry of Economic Affairs and Employment, 2019) and who all had intimate knowledge
of the healthcare sector, AI, and/or regulation of AIHT. Twelve informants from five different RDIclusters answered to the interviewee request. In October and November 2021, we conducted qualitative,
semi-structured interviews (Myers and Newman, 2007) that consisted of nine question categories: interviewee’s background, definition for AI, utilization and development of AI, role of AI in healthcare,
regulation of AI in healthcare, AI and AI Act proposal, AI and ethics, AI and data, and future of AI. The
average interview length was 60 minutes. Figure 1 summarizes interviewee-related information. Interviews have been transcribed non-verbatim. Presented quotes are our own translations from Finnish to
English. The interviewees are referred to as I-1 to I-12 in the remainder of this paper. We also reviewed
the regulations that currently regulate in some way AIHT to get a better understanding of the regulatory
context and for the data triangulation.

Figure 1. Summary of Interviewees.
Data analysis. We applied inductive content analysis, which is widely used in the field of nursing science (Kyngäs, 2020), but also in other fields of science to analyse qualitative data (Neuendorf, 2017).
Inductive content analysis is a discussion between the researcher and collected data, and it includes three
phases: data reduction, data grouping and the formation of concepts that can be used to answer the
research questions (Kyngäs, 2020). First, interview transcripts were read through several times. After
this, the raw data was coded into open codes, which could be either words or a sentence. Open codes
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were thematically grouped into subcategories, and these were thematically categorized into categories.
Figure 2 exemplifies the analysis and formulation of subcategory “Deceleration of AIHT development”.
We first analyzed the data on a more general level to answer questions of how different stakeholders
perceived the current regulation of AIHT (resulting in four categories and 15 subcategories), and how
they see the future of AI regulation (resulting in 3 categories and 20 subcategories). Then, we extracted
from these sub-categories those that indicated either a challenge or a (potential) consequence of current
and future AI regulation to answer the research question.

Figure 2. Formulation of subcategory.

4

Findings

We first summarize our findings on how AIHT is currently regulated in the EU and Finland, followed
by the challenges current regulation represents for AIHT developers. Then, we summarize our findings
regarding challenges related to a future European-wide AI regulation. Figure 3 summarizes our findings
in form of the categories and sub-categories we identified in answer to the research question.

Figure 3. Categorized findings.
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4.1

How is AI-based healthcare technology currently regulated in the EU
and Finland

In Europe, the European Commission steers the regulation of AI in healthcare technology. Before the
year 2017, there were three different directives that regulated MDs. However, due the development of
technology, these are replaced with the Medical Device Regulation (MDR) 2017/745, which became
effective on May 26th 2021, and the In Vitro Diagnostic Medical Device Regulation (IVDR) 2017/746,
which became effective on May 26th 2022 (European Commission, 2021b).
The purpose of these regulations is to protect public health and the health of single patients. Compared
with the previous MDD, the updated MDR requires every manufacturer to have a quality management
system regardless of their risk classification, a person who is responsible for regulatory compliance, and
a registration in the European Database on Medical Devices (EUDAMED). Moreover, reporting is required from MD manufacturers, and work distribution and liabilities between manufacturers, authorized
representatives, importers, and distributors must be defined individually. Per se, software products – and
thus also AIHT – belong to the highest risk class of MDs, and cybersecurity is added into safety requirements. Every device must have a unique device identifier to enhance the tracking of devices. A notified
body must be named to guarantee the competence of evaluating instances. (European Commission,
2020a.) IVDR sets requirements for tighter clinical evidence and conformity assessment and clarifies
responsibilities of manufacturers, authorized representatives, importers, and distributors (European
Commission, 2020b). Data privacy and protection of health information are regulated through the
GDPR, and ethical issues related to AI are considered in the EU guidelines on the Ethics of AI (European
Commission, 2019).
In addition, data usage is regulated also on a national level in Finland through the Biobank Act, the Act
on the Secondary Use of Health and Social Data, and the Genome Act that is currently under preparation: “In addition, the development of AI requires data and biological samples. So, from this point of
view, also the Biobank Act, the Act on the Secondary Use of Health and Social Data, and in future the
Genome Act, relate to the development of AI”. (I-5) Also, the Finnish Ministry of Social Affairs and
Health and the Finnish Institute for Health and Welfare indirectly regulate AI use in healthcare through,
for example, strict information security requirements that complicate the use of cloud services.
Adherence to the regulation(s) is supervised by the AIHT manufacturer, a notified body, and a supervisory authority. I-8 pointed out that the current regulation allows the development of AIHT: “In my
opinion, all AI solutions are possible within in current regulation, excluding totally autonomous AI
systems”. There are also benefits for companies that are able to show that their products comply with
the regulation, like the representative of large health technology company discussed: “In my job, the
regulation has a positive aspect, it is diacritical thing, because if we obtain the CE-mark, it separates
us from many start-up companies”. (I-2) Regulatory compliance can be used also in marketing of the
AIHT. Interviewees felt that the development of AI solutions is already heavily regulated, and that this
should be taken into account also when developing the regulation of AI in future.
To summarize, many existing regulations currently regulate AIHT on both the European and national
level, although only few of these regulations directly mention AI.

4.2

Challenges of current regulation of AI in healthcare

Interviewees recognized four challenges with the current regulation of AI in healthcare. All quote references in this section refer to Figure 4, which summarizes these challenges with representative quotes.
A major challenge in the development of AI-based healthcare technology is ambiguity that arises
within and between different regulations. Ambiguity was perceived as built-in the development of
MDs, because all those regulations are interpreted by supervisory authorities and notified bodies [Q1].
I-8, the small health technology company representative, also perceived that those interpretations depend on debates and choices made during the development of the technology, e.g., actions related to
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data or process management [Q2]. From the perspective of public healthcare, the justification of data
usage (e.g., for research, or for information management) influences what kind of regulation should be
complied with [Q3]. In addition, ambiguity arises from mismatches between different regulations, such
as the MDR and the GDPR. Interviewees also highlighted a need for clear guidance to decrease ambiguity [Q4]. This need for clarity of regulation was also emphasized in the context of sensitive personal
data by the regulatory senior specialist [Q5]. Unclear regulatory guidance may cause the need to seek
frameworks for interpretation from other public authorities [Q6].

Figure 4. Challenges of current regulation of AI in healthcare.
The current complexity of AI regulation in healthcare decelerates the development of AIHT. Training
an AI system in a “legally correct” way was perceived as challenging [Q7]. In addition, awareness of
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regulations that currently regulate AI system development is not always sufficient, as the representative
of MD supervision indicated [Q8]. The fulfilment of the MDR was perceived as a challenge in itself. As
the regulation is unclear and bureaucratic, it is very time-consuming to develop AIHT.
Another aspect and challenge related to the development and the use of AI-based solutions in healthcare
was the question of liability. From the perspective of one legal lobbying representative, it is challenging
to define how responsibilities are divided among those who participate in system development, and how
to define who of the participating parties is responsible for ensuring that requirements set by the regulation are actually fulfilled [Q9]. On the other hand, as the representative of a large health technology
company indicated, also the use of AI includes risks, limiting its use in healthcare [Q10].
A main challenge for AIHT development is the use of data. Currently, the GDPR and data privacy
policies are seen to limit the development of AI solutions [Q11]. Localisation requirements were seen
as challenges in cases where a lot of data and data management tools are required. Also, data access
rights and its management are a challenge for the data use [Q12]. Also, the national Act on the Secondary
Use of Health and Social Data, and data sensitivity was seen as a challenge. One concern was that too
strict data regulation may disable the whole AI sector.

4.3

Potential consequences of future regulation of AIHT

Interviewees pointed out several potential consequences arising from a future European AI Act for the
development and use of AIHT. All quote references in this section refer to Figure 5, which summarizes
these potential consequences and includes representative quotes.
The representative of consultancy perceived that the regulatory reform may cause overly strict regulation that will lead to a situation where development and productization of AIHT will move to less
regulated environments [Q13]. The representative of healthcare growth strategy sees it as questionable
that all AI solutions in healthcare are automatically high-risk products, which may cause unnecessary
risk-based classification [Q14]. From a national perspective, the representative of a large health technology company as well as a legal lobbying representative argued that too strict national regulation
will decrease organizations’ competitiveness in international markets, and hamper investment and
innovation [Q15 and Q16]. Moreover, it was seen that on a global perspective, strict and less-strict AI
regulation have started to tear countries and continents apart as the representative of small health technology company considered [Q17]. The representative research and education (I-2) was worried about
how Europe will fend versus China. A small health technology company representative (I-8) emphasized
that the development of innovative AI solutions requires an enabling innovation environment and regulation, otherwise there is a danger that good ideas will not be implemented and not be brought to the
market. A representative of legal lobbying (I-6) emphasized that regulation should enable innovation
and allow co-creation with patients.
An increased demand for professional services, such as legal services, is expected for AIHT development organizations, like in public healthcare [Q18]. The representative of healthcare growth strategy
indicated that as a consequence of this, also the lawyers that support AIHT providers will need increased
understanding [Q19]. Also, the representative of research and education (I-2) indicated that their organization will increase their expertise as part of their ecosystem and services to then have real experts who
are able to answer questions and create RDI co-operation. This, in turn, will increase the costs related
to AIHT development, as pointed out by a representative of legal lobbing [Q20]. The AI Act would
cause unequal treatment of diverse AI technologies, as one representative of legal lobbing saw it
[Q21].
In addition, as another representative of legal lobbing considered, some currently less regulated AIHT
- as they are no certified MDs - might fall under the AI Act and then would face heavy regulation.
Such technologies are, e.g., assistant technologies, welfare technologies and wearables [Q22]. In addition, the representative of a small health technology company argued that black-box technologies may
encounter challenges under the European AI Act.
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Figure 5. Potential consequences of future AIHT regulation.
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Interviewees expected that a dual-regulation is a likely consequence of the regulatory reform – if there
will be separate regulations for AI (= the AI Act) and for medical devices (= MDR), requirements from
both regulations must be fulfilled, as the small health technology company representative concluded
[Q23]. The AI Act is partly overlapping with existing regulation, such as the MDR and IVDR, as pointed
out by I-8. This may lead to conflicts between the AI Act and the MDR, as pointed out by I-11. More
generally, the AI Act was seen to cause increased difficulties with interpretation in relation to other
regulations such as the GDPR and national supplemental regulation, opening questions regarding what
is being regulated in which regulation [Q24].
From the perspective of supervision, the requirements set in the AI Act proposal also may lead to challenges in the evaluation of AIHT, e.g., regarding version control, because AI systems are not “locked”
and learn over time [Q25]. According to a legal lobbing representative, also a too small number of those
organizations that do evaluation will cause challenges and potential bottlenecks in the evaluation of
AIHT [Q26], which might delay bringing AIHT to market.
Finally, a deceleration of AIHT development can be expected as the representatives of different stakeholder groups, such as the comments of the research and education representative [Q27], the legislation
and political alignments representative [Q28], and the public healthcare representative [Q29] pointed
out.

5

Discussion

With this study, we contribute to the very recent IS research opening on the regulation of technology by
increasing understanding on the role of regulation as an environmental determinant that triggers and
shapes digital transformation (Hanelt et al., 2021). Collins et al. (2021: 13) proposed that future IS research should address the question “What can researchers and regulators do to keep up with the speed
of AI advances?” With the present study, we take a first step towards addressing this question by investigating how current regulation of AIHT and a potential future European AI Act – which can be seen as
a regulator’s answer to the advances in AI technology and the challenges these advances pose – affect
not only (1) the innovation and development of AIHT, but also (2) bringing new AIHT to market and
(3) the adoption and use of AIHT.
Figure 6 summarizes our main findings. We make visible potential consequences of the recent European
AI Act proposal, ranging from organization-level impacts such as an increase of AIHT development
costs, to industry-level impacts such as a deceleration of AIHT development and decreased competitiveness of Finnish/European AIHT providers and a danger that AIHT innovation start-ups might move
to less regulated countries.
One important finding is the existence of and challenges stemming from ambiguity in the current regulation of AIHT. This ambiguity mostly stems from differing and conflicting requirements set in different
regulations (e.g., MDR and GDPR). Already now, clear guidelines would be needed to decrease this
ambiguity. However, according to the interviewees, the AI Act would even add an additional layer of
ambiguity. Some earlier IS research has already pointed out that ambiguity in regulation can be problematic (see Väyrynen and Lanamäki, 2020), and our study confirms this. While one stated goal of the
AI Act is to “ensure legal certainty to facilitate investment and innovation in AI” (European Commission, 2021a, p. 3), our findings suggest that at least for AIHT, it would result in increased ambiguity and
a potential decrease in investment in and development of AIHT.
A recent study suggested that government regulation of AI systems may help users trust that an AI
system will deliver the service the user expects, and that this in turn may positively affect their willingness to share personal health information (Yan and Xu, 2021). As AI technologies require a lot of data
(Forcier et al., 2019), e.g., for training of AIHT, one could expect the AI Act to positively affect user’s
willingness to share data and thus positively affect development of future AIHT. However, if regulation
is ambiguous, the regulative legitimacy of a technology may be contested, because ambiguous regulation
leaves room for interpretation (Väyrynen and Lanamäki, 2020). As a result, the increased level of ambiguity regarding AIHT development may actually decrease the trust of users in AIHT.
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Another interesting finding concerns the evaluation of AIHT under the AI Act. Currently, the lack of
appropriate validation of AI technologies represents a challenge for integration of AIHT in clinical practice (Recht et al., 2020). The AI Act would require AIHT to undergo additional evaluation procedures
before they could be brought to market, which would tackle this recognized validation challenge. However, we found that this evaluation requirement may also lead to delays in bringing new AIHT innovations to the market, if not enough evaluation organizations exist, as currently already seems to be the
case with notified bodies.

Figure 6. Challenges for AIHT development and potential consequences of the European AI Act.
Nguyen et al. (2022) identified five research opportunities for future AI-focused IS research, including
the topic of “AI and markets”. Their (ibid: 196) product-centric view sees AI technology as a “product
with certain utility and costs for individual and organizations”, and “focuses on the economic activity,
people, and processes that surround efforts to produce, distribute, and use AI products”. They pointed
out that new players might emerge around AI products. Our study confirms this assumption: we identified new organizations for AIHT evaluation as such a potential new player emerging – not due to advances in AI development, but rather due to advances in AI regulation. More generally, our findings
may provide useful for future IS researchers interested in contributing to “AI and markets” research
themes, and we invite future IS research to be attentive to the role of legal regulation when investigating
AI-related market dynamics.
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Much of the current IS research on the digital transformation focuses on how an organization’s use of
digital technologies fuels disruptions which trigger strategic responses that in turn rely on the use of
digital technologies, to eventually enable changes in value creation paths (Vial, 2019). With this study,
we demonstrated that the regulation of technology affects where, when, and at what cost new AIHT
innovations are available for organizations to use. Regulation plays a key role in the digital transformation, and we invite future IS research to investigate in more detail different mechanisms through
which regulation affects digital transformation on the organization and industry level.

6

Conclusion

With this study, we sought to identify challenges that AIHT providers currently face regarding the regulation of AIHT and gain an understanding of the potential consequences of future AI regulation. We
contribute to the recent IS research opening on the legal regulation of technology.
A practical implication of our study for regulators is the identification of a need for a sufficient number
of evaluation bodies/companies for AIHT once the AI Act becomes effective. Our findings also have
practical implications in form of useful insights to managers of AIHT innovation start-ups who might
not yet have given that much thought how the AI Act potentially affects AIHT providers.
One limitation of the study is that we did not interview representatives of all central stakeholder groups
of the healthcare RDI cluster in Finland at this stage. We plan to do this in the next phase of this research
project. Another limitation is that this study has been conducted in one country only, and even though
we involved a wide array of stakeholders with intimate and diverse understanding of the phenomenon
we investigated, additional insights may be gained from involving more stakeholders, and conducting a
similar study in a different setting (e.g., different European countries). Nevertheless, this limitation
opens possibilities for future research to validate and extend our findings.

References
Ahmad, O.F., Stoyanov, D., and Lovat, L.B. (2020). “Barriers and pitfalls for artificial intelligence in
gastroenterology: Ethical and regulatory issues,” Techniques and Innovations in Gastrointestinal Endoscopy, 22(2), 80-84.
Allen, T.G. (2019). “Regulating artificial intelligence for a successful pathology future,” Archives of
Pathology and Laboratory Medicine, 143(10), 1175-1179.
Benbya, H., Pachidi, S., and Jarvenpaa, S. (2021). “Special Issue Editorial: Artificial Intelligence in
Organiztiations: Implications for Information Systems Research,” Journal of the Association for Information Systems, 22(2), 281-303.
Bester, J., Cole, C.M., and Kodish, E. (2016). “The limits of informed consent for an overwhelmed
patient: clinicians’ role in protecting patients and preventing overwhelm,” AMA Journal of Ethics,
18(9), 869-886.
Bérubé, M., Giannelia, T., and Vial, G. (2021). “Barriers to the Implementation of AI in Organizations:
Findings from a Delphi Study,” In Proceedings of the 54th Hawaii International Conference on System Sciences, 6702-6711.
Blind, K., Petersen, S. S., and Riillo, C. A. F. (2017). The impact of standards and regulation on innovation in uncertain markets. Research Policy, 46(1), 249-264.
Bohr, A., and Memarzadeh, K. (2020). “The rise of artificial intelligence in healthcare applications,”
Artificial Intelligence in Healthcare, 25-60.
Carter, S.M., Rogers, W., Win, K.T., Frazer, H., Richards, B., and Houssami, N. (2020). “The ethical,
legal and social implications of using artificial intelligence systems in breast cancer care,” The
Breast, 49, 25-32.
Collins, C., Dennehy, D., Conboy, K., and Mikalef, P. (2021). “Artificial intelligence in information
systems research: A systematic literature review and research agenda,” International Journal of Information Management, 60, Article 102383, 1-17.

Thirteenth Scandinavian Conference on Information Systems (SCIS2022), Helsinge, Denmark.

12

Regulation of AI-based Healthcare Technology

Currie, G., and Hawk, K.E. (2020). “Ethical and legal challenges of artificial intelligence in nuclear
medicine,” Seminars in Nuclear Medicine, 51(2), 120-125.
European Commission. (2019). Ethics guidelines for trustworthy AI. Retrieved Apr 8, 2022 from
https://digital-strategy.ec.europa.eu/en/library/ethics-guidelines-trustworthy-ai
European Commission. (2020a). Factsheet for manufacturers of medical devices. Retrieved Apr 08,
2022 from https://ec.europa.eu/health/sites/default/files/md_newregulations/docs/md_manufacturers_factsheet_en.pdf
European Commission. (2020b). Factsheet for manufacturers of in vitro diagnostic medical devices.
Retrieved Apr 08, 2022 from https://ec.europa.eu/health/sites/default/files/md_newregulations/docs/ivd_manufacturers_factsheet_en.pdf
European Commission. (2021a). Proposal for a regulation of the European parliament and of the council
laying down harmonised rules on artificial intelligence (artificial intelligence act) and amending certain union legislative acts. Retrieved Apr 8, 2022 from https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1623335154975anduri=CELEX%3A52021PC0206
European Commission. (2021b). Medical Devices. Retrieved Apr 08, 2022 from https://ec.europa.eu/health/md_sector/overview_en
Forcier, M. B., Gallois, H., Mullan, S., and Joly, Y. (2019). “Integrating artificial intelligence into health
care through data access: Can the GDPR act as a beacon for policymakers?” Journal of Law and the
Biosciences, 6(1), 317–335.
Gozman, D., Butler, T., and Lyytinen, K. (2020). “Regulation in the Age of Digitalization,” Call for
Papers on Special Issue of the Journal of Information Technology, 1-5.
Grant, K., McParland, A., Mehta, S., and Ackery, A. (2020). “Artificial intelligence in emergency medicine: surmountable barriers with revolutionary potential,” Annals of Emergency Medicine, 75(6),
721-726.
Grundstrom, C., Väyrynen, K., Iivari, N., and Isomursu, M. (2019). “Making Sense of the General Data
Protection Regulation – 4 Categories of Personal Data Access in Insurance Organizations,” Proceedings of the 52nd Hawaii International Conference on System Sciences (HICSS).
Hanelt, A., Bohnsack, R., Marz, D., and Antunes Marante, C. (2021). “A systematic review of the literature on digital transformations: Insights and Implications for strategy and organizational change,”
Journal of Management Studies 58(5), 1159-1197.
Hermon, R., Williams, P., and McCauley, V. (2021). “Software as a Medical Device (SaMD): Useful
or useless term?” In Proceedings of the 54th Hawaii International Conference on System Sciences,
3722-3731.
Higginbottom, G. (2004). "Sampling issues in qualitative research,” Nurse Researcher, 12(1), 7–19.
Jaremko, J.L., Azar, M., Bromwich, R., Lum, A., Cheong, L.H.A., Gibert, M., Laviolette, F., Gray, B.,
Reinhold, C., Cicero, M., Chong, J., Shaw, J., Rybicki, F.J., Hurrel, C., and Tang, A. (2019). “Canadian Association of radiologists white paper on ethical and legal issues related to artificial intelligence in radiology,” Canadian Association of Radiologists, 70(2), 107-118.
Karrenbauer, J., Wiesche, M., and Krcmar, Helmut (2019). “Understainding the benefits of agile software development in regulated environments,” 14th International Conference on
Wirtschaftsinformatik, February 24-27 2019, Siegen, Germany.
Kelly, J.C., Karthikesalingam, A., Suleyman, M., Corrado, G., and King, D. (2019). “Key challenges
for delivering clinical impact with artificial intelligence,” BMC Medicine, 17, 195.
Kyngäs, H. (2020). Inductive content analysis. In H. Kyngäs, K. Mikkonen and M. Kääriäinen (Eds.),
The application of content analysis in nursing science research (pp. 23-30). Springer International
Publishing AG.
Laï, M-C., Brian, M., and Mamzer, M-F. (2020). “Perceptions of artificial intelligence in healthcare:
findings from a qualitative survey study among actors in France,” Journal of Translational Medicine,
18, 14.
Mattei, P. (2020). “Digital governance in tax-funded European healthcare systems: from the Back office
to patient empowerment,” Israel Journal of Health Policy Research, 9, 3.

Thirteenth Scandinavian Conference on Information Systems (SCIS2022), Helsinge, Denmark.

13

Regulation of AI-based Healthcare Technology

May, A., Sagodi, A., Dremel, C., and van Giffen, B., (2020) "Realizing Digital Innovation from Artificial Intelligence," ICIS 2020 Proceedings. 6. https://aisel.aisnet.org/icis2020/digital_innovation/digital_innovation/6
Martin, N., and Matt, C. (2018). “Unblackboxing the Effects of Privacy Regulation on Startup Innovation,” Paper presented at the Thirty Ninth International Conference on Information Systems (ICIS
2018), San Francisco, CA, USA. https://aisel.aisnet.org/icis2018/security/Presentations/11
Ministry of Economic Affairs and Employment of Finland. (2019). Terveysalan kasvustrategian väliarviointi. Retrieved April 9, 2022 from https://tem.fi/documents/1410877/2921014/Terveysalan+kasvustrategian+v%C3%A4liarviointi/806d5b61-de4e-2ea9-0a93-43fa0bda281c/Terveysalan+kasvustrategian+v%C3%A4liarviointi.pdf (in Finnish)
Myers, M. D., and Newman, M. (2007). “The qualitative interview in IS research: Examining the craft,”
Information and Organization, 17(1), 2–26.
Neuendorf, K. (2017). The content analysis guidebook, 2nd edition. SAGE Publications Inc.
Nguyen, Q.N., Sidorova, A., and Torres, R. (2022). “Artificial Intelligence in Business: A Literature
Review and Research Agenda,” Communications of the Association for Information Systems, 50(1),
175-207.
Polit, D.F., and Beck, C.T. (2017). “Nursing Research: Generating and Assessing Evidence for Nursing
Practice,” 10th Edition, Wolters Kluwer Health, Philadelphia.
Sullivan, H.R., and Schweikart, S.J. (2019). “Are current tort liability doctrines adequate for addressing
injury caused by AI?” AMA Journal of Ethics, 21(2), e160-166.
Sunrise Winter, J., and Davidson, E. (2019). “Governance of artificial intelligence and personal health
information,” Digital Policy, Regulation and Governance, 21(3), 280-290.
Rebstadt, J., Remark, F., Fukas, P., Meier, P., and Thomas, O. (2022). "Towards Personalized Explanations for AI Systems: Designing a Role Model for Explainable AI in Auditing,”
Wirtschaftsinformatik 2022 Proceedings. 2. https://aisel.aisnet.org/wi2022/ai/ai/2
Reddy, S, Allan, S., Coghlan, S., and Cooper, P. (2020). “A governance model for the application of AI
in healthcare”, Journal of the American Medical Informatics Association, 27(3), 491-497.
Recht, M., Dewey, M., Dreyer, K., Langlotz, C., Niessen, W., Prainsack, B., and Smith, J.J. (2020).
“Integrating artificial intelligence into the clinical practice of radiology: challenges and recommendations,” European Radiology, 30(6), 3576-3584.
Reinecke, P., Kokshagina, O., and Karanasios, S. (2021). “Framing the Regulation of Artificial Intelligence-Based
Technologies,”
ECIS
2021
Research-in-Progress
Papers.
35.
https://aisel.aisnet.org/ecis2021_rip/35
Shintre, S., Roundy, K.A., and Dhaliwal, J. (2019). “Making machine learning forget,” Privacy Technologies and Policy, 11498, 72-83.
Smith, M., and Heath Jeffery, R.C. (2020). “Addressing the challenges of artificial intelligence in medicine,” Internal Medicine Journal, 50(10), 1278-1281.
Vial, G. (2019). “Understanding digital transformation: A review and research agenda,” Journal of Strategic Information Systems, 28(2), 118-144.
Väyrynen, K., and Lanamäki, A. (2020). “Policy Ambiguity and Regulative Legitimacy of Technology:
Legal indeterminacy as Result of an Ambiguous Taximeter Regulation,” ICIS 2020 Proceedings. 4.
Yan, A., and Xu, D.J. (2021). "AI for Depression Treatment: Addressing the Paradox of Privacy and
Trust with Empathy, Accountability, and Explainability" (2021). ICIS 2021 Proceedings. 15.
https://aisel.aisnet.org/icis2021/is_health/is_health/15

Thirteenth Scandinavian Conference on Information Systems (SCIS2022), Helsinge, Denmark.

14

